Dr Allan on the Investigation of Obinutuzumab Triplet Consolidation in MRD-Positive CLL
October 11th 2023John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .
Read More